Back to all studies
💉
Phase 3
Diabetes
in-person

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Ty…

Sponsored by Hoffmann-La Roche

Compensation

Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.

Duration

3 months

Location

Nationwide

About this study

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

Who can participate

  • • Adults aged 18–99
  • • All genders welcome
  • • Diagnosed with or experiencing obesity or overweight
  • • Able to attend in-person clinic visits

What's included

  • • Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.
  • • All study-related medical care at no cost
  • • Lab work, screenings, and physician consultations
  • • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.

Source: ClinicalTrials.gov record NCT07351058

Ready to Find a Research Study?

Explore clinical trials and paid research opportunities. Compensation varies by study and is never guaranteed.